<DOC>
	<DOCNO>NCT02531100</DOCNO>
	<brief_summary>This study design assess safety effectiveness BonyPid-500TM implantation intrabony peri-implantitis defect . BonyPid-500™ bone graft substitute , contain antibiotic drug - doxycycline , intend fill reconstruction bone defect cause peri-implantitis .</brief_summary>
	<brief_title>BonyPid-500TM Bone Graft Substitute Study</brief_title>
	<detailed_description>This pilot , randomize , single-blind , two arm control , multicenter study subject undergoing surgical treatment peri-implantitis disease . Eligible subject undergo surgical treatment randomly assign surgical intervention ( flap opening ) 1:1 ratio adjunct BonyPid-500TM implantation BonyPid-500TM implantation . Randomization stratify site number eligible implant , i.e. , single multiple . The study population include male female subject , 20 - 80 year age screening , diagnose peri-implantitis recommended surgical treatment peri-implantitis disease . Up 77 subject enrol study conduct two medical center Israel .</detailed_description>
	<mesh_term>Peri-Implantitis</mesh_term>
	<criteria>Male Female subject , 20 80 year age screening . Females childbearing potential must negative urine pregnancy test radiograph , dental hygienist cleaning , surgical procedure ( Note : Females childbearing age must agree use highly effective method contraception consistently correctly duration study period ) . Subjects minimum one osseointegrated implant periimplantitis . Subjects least one eligible implant within surgical area . Subjects bleed probe select implant without suppuration . Subjects select implant ( ) radiographic evidence , accord Xrays , : 1 . Intrabony defect 2 . Bone loss ≥ 3 mm 3 . Minimum 2 mm bone implant apex . Subjects must willing able provide write informed consent prior protocol specific procedure perform comply protocol requirement . Subjects hydroxyapatite ( HA ) coat implant , titanium plasma spray implant . Subjects distance implant &lt; 3 mm , &lt; 2 mm implant tooth . Subjects implant support removable denture . Subjects present severe active periodontitis . Subjects poor oral hygiene . Subjects select implant ( ) radiographic evidence horizontal bone loss . Subjects suffer Type 1 ( insulin dependent ) diabetes ; uncontrolled Type 2 diabetes . Diabetic subject must provide statement physician regard status diabetes , addition recent ( within 3 month ) document Hemoglobin ( Hgb ) A1c blood test &lt; 6.5 % . Pregnant woman woman intend become pregnant study period , breastfeed woman . Subjects know allergy contraindication tetracycline ( ) . Subjects current smoker smoker within 3 month prior screen . Subjects oral local antibiotic therapy last 4 week prior study enrollment . Subjects treat least 2 week medication know affect soft tissue condition within one month prior study enrollment ( e.g. , Phenytoin , Cyclosporine , Coumadin , NSAIDs ) . Subjects treat Oral IV use doxycycline last four week prior screen . Subjects presence active systemic infectious disease : hepatitis , HIV , history tuberculosis . Subjects condition , opinion Investigator , would place subject risk influence conduct study interpretation result . Subjects incapable follow study schedule reason , per Investigator 's discretion . Subjects currently enrol , recently participate ( within 30 day prior screen ) , plan enroll another study may conflict protocol requirement may confound subject result trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>